H.C. Wainwright Reiterates Buy Rating on Arbutus Biopharma (ABUS) Amid Progress on Pan-Coronavirus Treatment
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $8.00 price target on Arbutus Biopharma (NASDAQ: ABUS) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
